VANCOUVER, British Columbia, May 24, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR - News) (TSX:TKM.TO - News), a leading developer of RNA interference (RNAi) therapeutics, today provided a periodic update to its shareholders on the ongoing litigation with certain individuals from AlCana Technologies, Inc. in the Supreme Court of British Columbia.
